Life-2023-02 Esophagogastric Variceal Bleeding

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Aug 22, 2023

Keywords

ClinConnect Summary

This clinical trial, called Life-2023-02, is studying how effective certain growth inhibitors are after patients receive endoscopic treatment for acute esophagogastric variceal bleeding. This type of bleeding often occurs in patients with liver cirrhosis, which is a serious condition where the liver is damaged. The goal of the study is to see if these growth inhibitors can help prevent further bleeding after the initial treatment.

To be eligible for this trial, participants must be between the ages of 65 and 75 and have experienced acute bleeding from their esophagus or stomach due to liver cirrhosis, but they must be in stable condition without any active bleeding at the time of enrollment. Unfortunately, individuals who have had recent treatment for this type of bleeding, those in intensive care, pregnant women, or those with weakened immune systems cannot participate. If someone decides to take part in the trial, they can expect to receive careful monitoring and support throughout the study. This trial is currently recruiting participants, so it’s a good opportunity for those who meet the criteria and are looking for additional treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • acute esophagogastric bleeding with hepatic cirhosis;
• • stable status (no active bleeding)
• Exclusion Criteria:
• • endoscopic test limitation;
• • previous acute esophagogastric bleeding treatment history;
• • ICU;
• • pregnant;
• • Immunity disabled;